Drug Profile

Autoantigen peptide therapy - Diamante

Alternative Names: Peptide drug - Diamante

Latest Information Update: 20 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Diamante
Class Antirheumatics; Immunotherapies; Peptides
Mechanism of Action Cytokine modulators; Regulatory T-lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Rheumatoid arthritis

Most Recent Events

19 Mar 2026 Peptide based therapeutic is available for licensing as of 19 Mar 2026. https://www.diamante.tech/finance/ (Diamante website, March 2026)
19 Mar 2026 Diamante has US patent pending for autoantigen peptide therapy
19 Mar 2026 Diamante plans to launch autoantigen peptide therapy for Rheumatoid arthritis (Parenteral) in 2032

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com